BLCM

Bellicum Pharmaceuticals Inc

Healthcare


Presented:07/31/2015
Price:$20.35
Cap:$0.53B
Current Price:$0.07
Cap:$0.00B

Presented

Date07/31/2015
Price$20.35
Market Cap$0.53B
Ent Value$0.42B
P/E RatioN/A
Book Value$7.03
Div Yield0%
Shares O/S26.26M
Ave Daily Vol299,422
Short IntN/A

Current

Price$0.07
Market Cap$0.00B
Bellicum Pharmaceutivals, Inc. is a clinical stage biopharmaceutical company that engages in the development of novel cellular immunotherapies for various forms of cancer, solid tumors, and orphan inherited blood disorders. It develops chemical induction of dimerization technology platform to engineer and control components of the immune system. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

Publicly traded companies mentioned herein: Bellicum Pharmaceuticals Inc (BLCM), bluebird bio Inc (BLUE), Juno therapeutics Inc (JUNO), Kite Pharma Inc (KITE)

Highlights

In the presenter's opinion, Bellicum Pharmaceuticals (BLCM) is one of the most mischaracterized companies in the biotech arena. It is often thought of and referred to as a CAR T (chimeric antigen receptor T-cell) play and lumped in with companies such as bluebird bio, Juno and Kite as a cancer-focused development company. However, the presenter is long the stock due to BLCM's broader, but inclusive of oncology, cell therapy safety switch technology. Its CaspaCIDe product candidate, BPX-501, is being developed is an adjunct T cell therapy administered after allogeneic hematopoietic stem cell transplantation (HSCT). . Generally speaking, the presenter explained how T cells in transplants often cause graft-versus-host disease (GvHD), which is potentially fatal. In BLCM’s own words, “BPX-501 is designed to decrease the risk of including T cells with the transplant by enabling the elimination of donor T cells through the triggering of the CaspaCIDe safety switch upon emergence of GvHD via a single dose of rimiducid (AP1903)”. The presenter believes that the data are conclusive and said that infusing larger numbers of haploidentical (half match) donor T cells engineered with CaspaCIDe leads to much better infection control.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.